Cyclophosphamide, VELCADE, DOXIL, and Dexamethasone, (CVDD) in Newly Diagnosed Patients With Multiple Myeloma (MM)
Status:
Completed
Trial end date:
2013-05-01
Target enrollment:
Participant gender:
Summary
Cyclophosphamide is a chemotherapy agent with known activity in myeloma. The new regimen that
we will test in this study is called CVDD and contains Cyclophosphamide with Bortezomib
(VELCADE), Pegylated Liposomal Doxorubicin (DOXIL®, PLD), and Dexamethasone (VDD).
The purpose of this study is to determine if the addition of another type of chemotherapy
agent, Cyclophosphamide, to the regimen VDD (CVDD) is well tolerated and improves response
rates in myeloma. We will also find the highest safe dose of the study drugs taken together
that a patient can tolerate, and how long it takes for multiple myeloma patients to respond
after they have taken the study drugs and how long the response lasts.
Phase:
Phase 1/Phase 2
Details
Lead Sponsor:
H. Lee Moffitt Cancer Center and Research Institute
Collaborators:
Millennium Pharmaceuticals, Inc. Ortho Biotech, Inc.